Cardiology trials often adopt composite endpoints that combine several events of clinical interest as the primary efficacy outcome. Time-to-first-event approaches follow the recommendations of regulatory agencies. But composite outcomes that only consider the first event are suboptimal for a chronic disease such as heart failure (HF), which is characterized by recurrent HF hospitalizations since repeat…